Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Friday, December 7, 2012

Ataluren receives validation of marketing approval by EMA

Ataluren, a new drug made by PTC Therapeutics, yesterday announced that it had received validation of a marketing authorization application for Ataluren by the European Medicines Agency (EMA) for the treatment of Duchenne Muscular Dystrophy  (DMD).

This seems to mean that it is at least being considered for approval which will ultimately lead to it's approval for sale by the EMA. Although in this case it is being marketed for nonsense mutations in DMD, it should in theory be of some help to people who have a nonsense mutation of any genetic disorder. Typically, nonsense mutations make up about 5-10% of cases of a genetic disorder, and with FMO3 mutations it is likely to be around this amount.

missense and nonsense mutation analogy
Nonsense mutations are a 'severe' type of mutation. In the case of FMO3, which is a 532 amino acid sequence, it means that a false stop is inserted into the 532 sequence somewhere in the sequence (rather than at the end where a stop codon should be), and the FMO3 protein does not then get properly formed.

So this is an exciting milestone announcement by PTC Therapeutics, but presumably it still has a way to go before being a drug available in Europe.  

Official press release for the Ataluren announcement  
PTC page on Ataluren
Wikepedia entry for nonsense mutation


0 comments:

Post a Comment